Last reviewed · How we verify
NCT02991846: GITMO-GVCrOSy
A Prospective Observational Study for Evaluating CGVHD
trial in Chronic Graft-Versus-Host Disease in 248 participants. Completed in 22 November 2022.
22 November 2022
Quick facts
| Lead sponsor | Gruppo Italiano Trapianto di Midollo Osseo |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 248 |
| Start date | 1 September 2017 |
| Primary completion | 22 November 2022 |
| Estimated completion | 22 November 2022 |
| Sites | 27 locations across Italy |
Conditions studied
- Chronic Graft-Versus-Host Disease — all drugs for Chronic Graft-Versus-Host Disease →
Sponsor
Gruppo Italiano Trapianto di Midollo Osseo — full company profile →
Who can join
Eligibility, any sex, with Chronic Graft-Versus-Host Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospective, observational, multicentre, spontaneous, non-interventional study This study will evaluate all consecutive patients who develop chronic graft-versus-host disease, reported by the Italian GITMO centers according to a standardized Web platform for real-time, onsite data collection. The platform for data collection will be based on a software prototype developed by the Clinica di Ematologia di Ancona Transplant Center for the management of patients with chronic graft-versus-host disease. This software has been integrated with algorithms that automatically determine: severity of chronic graft-versus-host disease and overall response according to the 2015 NIH consensus criteria.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02991846
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Graft-Versus-Host Disease
Currently open trials in the same condition.
- NCT07138196 — A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease · Phase 1 · recruiting
- NCT06688942 — Digital Health Intervention to Promote Quality of Life in Adults With Chronic Graft Versus Host Disease · NA · active not recruiting
- NCT05690971 — Psychosocial Mobile App for Chronic Graft-Versus-Host Disease · NA · active not recruiting
- NCT02669251 — Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hemato · Phase 1, PHASE2 · active not recruiting
Other Gruppo Italiano Trapianto di Midollo Osseo trials
Trials by the same sponsor.
- NCT06790680 — GITMO AML/MDS-Relapse Registry Study · completed
- NCT04506320 — Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma · completed
- NCT04412811 — Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT · completed
- NCT03270748 — Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies · Phase 2 · completed
- NCT04476199 — Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02991846 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gruppo Italiano Trapianto di Midollo Osseo
- Last refreshed: 25 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02991846.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing